InMed Pharmaceuticals (INM) Life Sciences Virtual Investor Forum 2025 summary

Strategic focus and leadership

• Pipeline targets CB1 and CB2 receptors with proprietary small molecule drug candidates for Alzheimer's, ocular disease, and dermatology.

• Leadership team is highly experienced in drug development and commercialization.

• Two operating segments: drug development and BayMedica for commercializing rare cannabinoids.

• Clean balance sheet with no debt and a small, efficient team.

• Plans to expand team as programs advance to later stages.

Drug development programs

• INM-901 for Alzheimer's is in preclinical testing, showing reduced neuroinflammation, neuroprotection, and improved cognition in animal models.

• INM-089 targets dry age-related macular degeneration, demonstrating preservation and healing of retinal cells in animal studies.

• INM-755, a cannabinol cream, completed phase two trials for chronic itch in epidermolysis bullosa, showing clinically meaningful improvement in 66% of patients.

• Prioritization is given to INM-901 due to higher unmet need and promising data.

• No-go criteria are based on preclinical study outcomes; both lead programs continue development.

Financial and partnership outlook

• $9.3 million in cash as of September 30, providing about one year of runway.

• Market cap is approximately $5.6 million with a small share float.

• Actively seeking strategic partners to accelerate development and share costs, especially for INM-755 and preclinical assets.

• Collaborates with academic experts globally for disease-specific research.

• Key catalysts for 2026 include securing strategic partnerships and presenting new data at scientific conferences.